Mark James Litton, Chief Executive Officer at Athira Pharma, Inc. (ATHA), sold 7,960 shares at $2.69 ($21K) on 2022-06-23, disclosed to the SEC on 2022-06-24.
Open-market sale of $21k ATHA by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| ATHA | SELL | 2025-07-02 | $7K | — | Filing → |
| ATHA | SELL | 2025-01-03 | $14K | — | Filing → |
| ATHA | SELL | 2024-09-05 | $3K | — | Filing → |